Affimed Announces Fourth Quarter and Year End 2017 Financial Results and Corporate Update Conference Call March 13, 2018
Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares February 15, 2018
Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas February 1, 2018
Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH December 11, 2017
